Description
Approved accessible “avelumab injection”
BAVENCIO is a programmed death ligand-1 (PD-L1) blocking antibody indicated for:
Merkel Cell Carcinoma (MCC)
• Adults and pediatric patients 12 years and older with metastatic MCC. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be
contingent upon verification and description of clinical benefit in confirmatory trials.
Urothelial Carcinoma (UC)
• Maintenance treatment of patients with locally advanced or metastatic UC that has not progressed with first-line platinum-containing chemotherapy.
• Patients with locally advanced or metastatic UC who:
• Have disease progression during or following platinum-containing chemotherapy.
• Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
Renal Cell Carcinoma (RCC)
• First-line treatment, in combination with axitinib, of patients with advanced RCC.
How To access avelumab injection?
BAVENCIO (avelumab) injection, for intravenous use Initial U.S. Approval: 2017
To access avelumab injection sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN’s Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj)
